All News Alterity Therapeutics Limited Nasdaq

Equities

ATHE

US02155X2053

Delayed Nasdaq Other stock markets 08:36:06 03/05/2024 pm IST			5-day change	1st Jan Change
2.07 ^USD	-3.27%		-17.53%	-16.87%

29/04	Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases	CI
16/04	ADRs End Lower, Purple Biotech Ltd. Declines 29%	DJ

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases	29/04	CI
ADRs End Lower, Purple Biotech Ltd. Declines 29%	17/04	DJ
ADRs End Lower, Leju Holdings Ltd. Declines 72%	13/04	DJ
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%	12/04	DJ
ADRs Close Lower; VIA Optronics AG Declines 30%	11/04	DJ
Top Midday Gainers	10/04	MT
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund	26/03	AQ
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund	26/03	MT
Alterity Therapeutics : Receives a $3.9 million Research & Development Tax Incentive Refund	26/03	PU
Genetic Technologies Appoints CFO	25/03	MT
Alterity Therapeutics : Voting ahead of attending the Meeting - Form 6-K	15/03	PU
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	29/02	CI
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023	28/02	CI
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%	23/02	MT
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	06/02	AQ
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	06/02	CI
Alterity Therapeutics Advances Phase Two Multiple System Atrophy Trial Following Committee Recommendation	06/02	MT
Alterity Therapeutics Completes Securities Purchase Plan	02/02	MT
Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week	29/01	AQ
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones	22/01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Alterity Therapeutics Limited Nasdaq

Equities

ATHE

US02155X2053

All News

Filters